+Vote!
Medical News Today (Free subscription) | 07/19/2008
Patients benefit from a team approach at the new Coleman Foundation Comprehensive Clinic for Gastrointestinal Cancers at Rush University Medical Center. Experts in gastroenterology, medical oncology, surgery, radiation oncology, pathology and psychosocial oncology as well as nutrition and genetics come together to meet with new patients and develop a defined treatment plan.
+Vote!
The News Market (Free subscription) | 06/26/2008
Roche announced that new data from two studies that confirm that patients taking the chemotherapy pill Xeloda live longer than those receiving intravenous (IV) chemotherapy 5-FU/FA.
+Vote!
Red Orbit (Free subscription) | 04/23/2008
Biopharmaceutical firm Micromet has initiated a Phase I clinical trial with its BiTE antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers.
+Vote!
Medical News Today (Free subscription) | 04/23/2008
People with oesophageal cancer are often enduring serious symptoms for over a year before seeking help according to a report launched by the Northern Ireland Cancer Registry at Queen's.The report, entitled Monitoring Care of Patients with Upper Gastrointestinal cancers: 2005, compares care for patients diagnosed with cancers of the oesophagus and stomach in 1996, 2001 and 2005.
+Vote!
Medical News Today (Free subscription) | 04/08/2008
Increased consumption of teas rich in catechins is associated with reduced risk of stomach, colon and other gastrointestinal cancers. However, the effects of digestion on the anticancer activity of tea catechins have largely been ignored.
+Vote!
Physorg (Free subscription) | 04/07/2008
Increased consumption of teas rich in catechins is associated with reduced risk of stomach, colon and other gastrointestinal cancers. However, the effects of digestion on the anticancer activity of tea catechins have largely been ignored. A study by nutrition researchers at The Ohio State University and Purdue University found that the digestive process could both alter the structure of the tea catechins...
+Vote!
Market Wire (Free subscription) | 01/28/2008
MONTREAL, QUEBEC (MARKET WIRE) MethylGene Inc. (TSX: MYG), along with its collaborator Pharmion Corporation (NASDAQ: PHRM), today updated clinical data from the Companies' MGCD0103 Phase I/II combination trial with Gemzar(R) (Trial 006). The data were presented in a poster session at the 2008 Gastrointestinal Cancers Symposium in Orlando.
+Vote!
Medical News Today (Free subscription) | 01/28/2008
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced that it has presented safety data from a Phase 1 dose-escalation study of picoplatin, the Company's lead product candidate, at the 2008 Gastrointestinal Cancers Symposium, a meeting of the American Society of Clinical Oncology (ASCO) which is being held in Orlando, Fla.
1Vote!
Medical News Today (Free subscription) | 01/25/2008
New research on the treatment of gastrointestinal cancers is being presented at the 5th annual Gastrointestinal Cancers Symposium, being held January 25-27 at the Orlando World Center Marriott. The presscast highlighting noteworthy studies can be accessed here.
+Vote!
Medical News Today (Free subscription) | 01/25/2008
Roche announced that a total of 33 abstracts involving its oral chemotherapy Xeloda(R) have been accepted for presentation at the 2008 Gastrointestinal Cancers Symposium in Orlando, Fla., from Jan. 25 to 27. Five poster presentations based on U.S. data offer additional knowledge about Xeloda. Two of these U.S.
1Vote!
PR News Wire (Free subscription) | 01/24/2008
- U.S. Data Highlights Oral Xeloda versus Standard Infusional Chemotherapy
in Gastroesophageal and Colorectal Cancers -
NUTLEY, N.J., Jan. 24 /PRNewswire/ -- Roche announced today that a
total of 33 abstracts involving its oral chemotherapy Xeloda(R) have been
accepted for presentation at the 2008 Gastrointestinal Cancers Symposium in
Orlando, Fla., from Jan. 25 to 27.
Five poster presentations...
1Vote!
Business Wire (Free subscription) | 01/23/2008
BOSTON & PERTH, Australia--(BUSINESS WIRE)--pSivida Limited (NASDAQ: PSDV)(ASX: PSD)(FF: PSI), a global drug delivery company, today announced that the final results of the recently
+Vote!
Medical News Today (Free subscription) | 01/16/2008
Twenty-five leading oncology fellows from across the globe will receive a Merit Award from The ASCO Cancer Foundation for their outstanding contributions to cancer research of the gastrointestinal tract. These young investigators will be honored at the 2008 Gastrointestinal (GI) Cancers Symposium, which takes place January 25-27 in Orlando.
+Vote!
Medical News Today (Free subscription) | 01/07/2008
For the fifth consecutive year, key research on the prevention, screening and treatment of GI cancers will be the focus of the Gastrointestinal Cancers Symposium press program. Study authors will discuss notable research in an embargoed presscast (press briefing via live webcast) on January 23 from 1:00 to 2:00 PM (EST).
+Vote!
Medical News Today (Free subscription) | 12/14/2007
Science and Multidisciplinary Management of GI MalignanciesThe fifth annual Gastrointestinal Cancers Symposium is a three-day multidisciplinary meeting that will serve as an open forum on the latest clinical strategies for the prevention, screening and treatment of gastrointestinal cancers. [click link for full article]
